TY - JOUR
T1 - Five-year local control in a phase II study of hypofractionated intensity modulated radiation therapy with an incorporated boost for early stage breast cancer
AU - Freedman, Gary M.
AU - Anderson, Penny R.
AU - Bleicher, Richard J.
AU - Litwin, Samuel
AU - Li, Tianyu
AU - Swaby, Ramona F.
AU - Ma, Chang Ming Charlie
AU - Li, Jinsheng
AU - Sigurdson, Elin R.
AU - Watkins-Bruner, Deborah
AU - Morrow, Monica
AU - Goldstein, Lori J.
N1 - Copyright © 2012 Elsevier Inc. All rights reserved.
PY - 2012/11/15
Y1 - 2012/11/15
N2 - Purpose: Conventional radiation fractionation of 1.8-2 Gy per day for early stage breast cancer requires daily treatment for 6-7 weeks. We report the 5-year results of a phase II study of intensity modulated radiation therapy (IMRT), hypofractionation, and incorporated boost that shortened treatment time to 4 weeks. Methods and Materials: The study design was phase II with a planned accrual of 75 patients. Eligibility included patients aged ≥18 years, Tis-T2, stage 0-II, and breast conservation. Photon IMRT and an incorporated boost was used, and the whole breast received 2.25 Gy per fraction for a total of 45 Gy, and the tumor bed received 2.8 Gy per fraction for a total of 56 Gy in 20 treatments over 4 weeks. Patients were followed every 6 months for 5 years. Results: Seventy-five patients were treated from December 2003 to November 2005. The median follow-up was 69 months. Median age was 52 years (range, 31-81). Median tumor size was 1.4 cm (range, 0.1-3.5). Eighty percent of tumors were node negative; 93% of patients had negative margins, and 7% of patients had close (>0 and <2 mm) margins; 76% of cancers were invasive ductal type: 15% were ductal carcinoma in situ, 5% were lobular, and 4% were other histology types. Twenty-nine percent of patients 29% had grade 3 carcinoma, and 20% of patients had extensive in situ carcinoma; 11% of patients received chemotherapy, 36% received endocrine therapy, 33% received both, and 20% received neither. There were 3 instances of local recurrence for a 5-year actuarial rate of 2.7%. Conclusions: This 4-week course of hypofractionated radiation with incorporated boost was associated with excellent local control, comparable to historical results of 6-7 weeks of conventional whole-breast fractionation with sequential boost.
AB - Purpose: Conventional radiation fractionation of 1.8-2 Gy per day for early stage breast cancer requires daily treatment for 6-7 weeks. We report the 5-year results of a phase II study of intensity modulated radiation therapy (IMRT), hypofractionation, and incorporated boost that shortened treatment time to 4 weeks. Methods and Materials: The study design was phase II with a planned accrual of 75 patients. Eligibility included patients aged ≥18 years, Tis-T2, stage 0-II, and breast conservation. Photon IMRT and an incorporated boost was used, and the whole breast received 2.25 Gy per fraction for a total of 45 Gy, and the tumor bed received 2.8 Gy per fraction for a total of 56 Gy in 20 treatments over 4 weeks. Patients were followed every 6 months for 5 years. Results: Seventy-five patients were treated from December 2003 to November 2005. The median follow-up was 69 months. Median age was 52 years (range, 31-81). Median tumor size was 1.4 cm (range, 0.1-3.5). Eighty percent of tumors were node negative; 93% of patients had negative margins, and 7% of patients had close (>0 and <2 mm) margins; 76% of cancers were invasive ductal type: 15% were ductal carcinoma in situ, 5% were lobular, and 4% were other histology types. Twenty-nine percent of patients 29% had grade 3 carcinoma, and 20% of patients had extensive in situ carcinoma; 11% of patients received chemotherapy, 36% received endocrine therapy, 33% received both, and 20% received neither. There were 3 instances of local recurrence for a 5-year actuarial rate of 2.7%. Conclusions: This 4-week course of hypofractionated radiation with incorporated boost was associated with excellent local control, comparable to historical results of 6-7 weeks of conventional whole-breast fractionation with sequential boost.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Breast Neoplasms/pathology
KW - Carcinoma in Situ/pathology
KW - Combined Modality Therapy/methods
KW - Dose Fractionation, Radiation
KW - Female
KW - Humans
KW - Mastectomy, Segmental
KW - Middle Aged
KW - Neoplasm Recurrence, Local/pathology
KW - Neoplasm Staging
KW - Neoplasms, Second Primary/pathology
KW - Photons/therapeutic use
KW - Quality of Life
KW - Radiotherapy, Intensity-Modulated/adverse effects
KW - Skin/radiation effects
KW - Time Factors
KW - Tumor Burden
UR - http://www.scopus.com/inward/record.url?scp=84872012344&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000310565300023&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1016/j.ijrobp.2012.01.091
DO - 10.1016/j.ijrobp.2012.01.091
M3 - Article
C2 - 22580118
SN - 0360-3016
VL - 84
SP - 888
EP - 893
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 4
ER -